Disseminated cryptococcosis associated with administration of eculizumab.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Cryptococcus neoformans; disseminated cryptococcosis; eculizumab
PURPOSE: A case report of fatal disseminated cryptococcosis in a patient treated with eculizumab is presented along with a review of literature suggesting a possible etiologic mechanism.
SUMMARY: A 23-year-old man with a history of minimal change nephrotic syndrome was hospitalized for acute kidney injury and abdominal pain and swelling. He was found to have disseminated pneumococcal disease, including peritonitis, bacteremia, and pulmonic endocarditis. The patient developed evidence of microangiopathic hemolytic anemia, leading to a diagnosis of atypical hemolytic uremic syndrome, and was started on eculizumab. The patient initially improved but developed septic shock 18 days after the first dose of eculizumab. All subsequent blood, respiratory, and intraabdominal cultures grew
CONCLUSION: A 23-year-old man developed fatal disseminated cryptococcosis after treatment with eculizumab.
Kidney & Diabetes
Clancy, Megan; McGhan, Ryan; Gitomer, Jeremy; Inocencio, Ana Marie; Aldrich, Christina; Iaderosa, Roberto; and Stevens, Ryan, "Disseminated cryptococcosis associated with administration of eculizumab." (2018). Articles, Abstracts, and Reports. 196.